Kura Oncology, Inc. (NASDAQ:KURA) Stock Holdings Lessened by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. lessened its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 5.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 36,311 shares of the company’s stock after selling 2,207 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Kura Oncology were worth $522,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Pale Fire Capital SE bought a new position in shares of Kura Oncology during the third quarter valued at approximately $92,000. E Fund Management Co. Ltd. boosted its position in Kura Oncology by 12.2% during the 3rd quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company’s stock valued at $109,000 after purchasing an additional 1,301 shares during the period. AXQ Capital LP bought a new position in Kura Oncology during the 3rd quarter worth $118,000. China Universal Asset Management Co. Ltd. grew its stake in Kura Oncology by 352.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,590 shares of the company’s stock worth $124,000 after buying an additional 6,692 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its position in Kura Oncology by 11.1% in the third quarter. Teacher Retirement System of Texas now owns 15,490 shares of the company’s stock worth $141,000 after buying an additional 1,544 shares during the period.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on KURA shares. HC Wainwright reissued a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a report on Monday. Wedbush restated an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a research report on Wednesday, February 28th. JMP Securities lifted their price target on Kura Oncology from $22.00 to $32.00 and gave the company a “market outperform” rating in a report on Wednesday, January 31st. Finally, StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday, April 15th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and a consensus target price of $28.28.

Kura Oncology Stock Performance

KURA opened at $19.00 on Friday. Kura Oncology, Inc. has a 1-year low of $7.41 and a 1-year high of $24.17. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -9.13 and a beta of 0.85. The business has a 50 day moving average price of $20.70 and a two-hundred day moving average price of $15.44. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.26 and a quick ratio of 12.26.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.01. During the same period last year, the business posted ($0.49) earnings per share. Research analysts predict that Kura Oncology, Inc. will post -2.35 EPS for the current fiscal year.

Insider Buying and Selling at Kura Oncology

In other news, COO Kathleen Ford sold 1,496 shares of Kura Oncology stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $17.80, for a total value of $26,628.80. Following the transaction, the chief operating officer now owns 21,602 shares of the company’s stock, valued at approximately $384,515.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, COO Kathleen Ford sold 1,496 shares of the business’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $17.80, for a total transaction of $26,628.80. Following the sale, the chief operating officer now directly owns 21,602 shares of the company’s stock, valued at $384,515.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Thomas James Doyle sold 2,318 shares of the stock in a transaction on Monday, January 29th. The shares were sold at an average price of $17.80, for a total value of $41,260.40. Following the completion of the transaction, the senior vice president now owns 48,093 shares of the company’s stock, valued at approximately $856,055.40. The disclosure for this sale can be found here. In the last three months, insiders sold 5,867 shares of company stock valued at $104,433. 5.50% of the stock is owned by insiders.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.